At what enterprise value was HTL BIOTECHNOLOGY acquired in 2018?

During the acquisition of HTL BIOTECHNOLOGY by BRIDGEPOINT in 2018, the transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b EUR.

What was the EV/EBITDA of HTL BIOTECHNOLOGY when it was acquired by BRIDGEPOINT?

The estimated EV/EBITDA multiple for HTL BIOTECHNOLOGY is in the range of 15x - 25x.

When was HTL BIOTECHNOLOGY acquired by BRIDGEPOINT?

HTL BIOTECHNOLOGY was acquired by BRIDGEPOINT in 2018.

What was the revenue of HTL BIOTECHNOLOGY at the time of the deal?

The revenue of HTL BIOTECHNOLOGY at the time of the deal is estimated to be in the range of 50M - 100M EUR.

What was the EBITDA of HTL BIOTECHNOLOGY during the acquisition?

HTL BIOTECHNOLOGY's EBITDA is estimated to be in the range of 25M - 50M EUR.

How is the data for the HTL BIOTECHNOLOGY acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the HTL BIOTECHNOLOGY deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://naxicap.com/wp-content/uploads/2018/10/CP-HTL-8-10-2018-VD-FR.pdf

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaHTL BIOTECHNOLOGY

10/2018

HTL BIOTECHNOLOGY acquired by BRIDGEPOINT

FRANCE Life Sciences / Pharma & Biotech / CDMO EV 500M - 1.5b EUR

Context

Bridgepoint has acquired a majority stake in HTL, the specialized producer of hyaluronic acid, in a secondary LBO transaction from Naxicap Partners. This operation follows a period of rapid development under the previous sponsor, which had orchestrated a management buy-in (MBI) only eighteen months prior. In this new capital structure, Naxicap Partners retains a significant minority interest, signaling continued confidence in the company's growth trajectory and industrial potential. The rationale for the transaction is rooted in HTL,s exceptional profitability and its unique position in a high-barrier-to-entry niche of the biotechnology sector. With Bridgepoint,s support, HTL aims to accelerate its international transformation, moving beyond its historical European stronghold to capture market share in North America and Asia.

HTL BIOTECHNOLOGY, which reported an EBITDA margin of in 2018, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in the late 20th century, HTL is a leading global biotechnology company specializing in the development, production, and purification of pharmaceutical-grade hyaluronic acid and other bio-sourced polymers. Based in Brittany, the company utilizes advanced fermentation and purification processes to supply high-purity ingredients to the global healthcare industry. Its value proposition is centered on technical excellence and the ability to provide customized molecular weights for sensitive medical applications, including dermatology for wrinkle filling, ophthalmology for cataract surgery, and rheumatology for joint treatments. HTL,s strategy focuses on continuous innovation through significant R&D investments and the expansion of its industrial capacities to maintain a leadership position in the high-end biopolymer market. By maintaining a discreet but critical role in the pharmaceutical supply chain, the company ensures that global medical device and pharma manufacturers have access to safe, natural, and highly effective components for life-changing medical treatments.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2018

2017

Other operations with HTL BIOTECHNOLOGY

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
02/2022	MONTAGU PRIVATE EQUITY / PARTNERS GROUP	HTL BIOTECHNOLOGY	FRANCE	CDMO

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 50M - 100M EUR

EBITDA range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of HTL BIOTECHNOLOGY by BRIDGEPOINT are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: htl biotechnology

Acquirer: bridgepoint